#TumorTalk is back today at 4p EST! We’re diving into new data on temozolomide re-challenge for Grade 2 and 3 IDH-mutant gliomas and what actually happens at first progression when you go back to TMZ in this molecularly distinct group. ­- Join Drs. David Schiff, Sohil Patel, and Lalanthic Yogendran as they walk through response patterns, clinical decision points, and how this strategy fits into the evolving landscape of lower-grade glioma management. ­- Hosted by seattlesciencefoundation and jneurooncol. ­- 🔗 Link in bio! — #braintumor #gbm